Short Interest in Indaptus Therapeutics, Inc. (NASDAQ:INDP) Expands By 88.8%

Indaptus Therapeutics, Inc. (NASDAQ:INDP) was the target of a large growth in short interest in July. As of July 15th, there was short interest totaling 259,720 shares, a growth of 88.8% from the June 30th total of 137,594 shares. Based on an average daily volume of 75,877 shares, the days-to-cover ratio is presently 3.4 days. Approximately 0.3% of the shares of the company are short sold.

Indaptus Therapeutics Stock Down 10.4%

Indaptus Therapeutics stock opened at $1.29 on Friday. The stock has a 50-day moving average price of $2.70 and a 200 day moving average price of $2.34. The company has a market capitalization of $146.08 million, a price-to-earnings ratio of -0.08 and a beta of 1.11. Indaptus Therapeutics has a 52 week low of $0.92 and a 52 week high of $8.69.

Indaptus Therapeutics (NASDAQ:INDP) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($1.87) by $1.64.

Analysts Set New Price Targets

Several research firms have recently commented on INDP. Weiss Ratings reiterated a “sell (e+)” rating on shares of Indaptus Therapeutics in a research note on Friday, July 17th. Wall Street Zen raised shares of Indaptus Therapeutics to a “hold” rating in a report on Saturday, June 27th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Institutional Trading of Indaptus Therapeutics

A hedge fund recently bought a new stake in Indaptus Therapeutics stock. Virtu Financial LLC bought a new position in shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned about 1.72% of Indaptus Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 7.06% of the company’s stock.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.